MedTrace Logo

Safety Study of TAK-128 in Subjects With Diabetic Peripheral Neuropathy

NCT00756041 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 221

Last updated 2012-02-28

No results posted yet for this study

Summary

The purpose of this study is to determine the safety of TAK-128, once daily (QD), for treatment of diabetic peripheral neuropathy

Conditions

  • Diabetic Neuropathies

Interventions

DRUG

TAK-128

TAK-128 100 mg tablet, orally, once daily for up to 1 year.

Sponsors & Collaborators

Principal Investigators

  • Sr. Medical Director Clinical Science · Takeda

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2006-09-30
Completion
2006-09-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00756041 on ClinicalTrials.gov